Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Status and Forecast (2016-2027)
  • 1.3.2 Global Targeted Drug BRAF Inhibitors for NSCLC Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Targeted Drug BRAF Inhibitors for NSCLC Supply by Company

• 2.1 Global Targeted Drug BRAF Inhibitors for NSCLC Sales Value by Company
• 2.2 Targeted Drug BRAF Inhibitors for NSCLC Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Targeted Drug BRAF Inhibitors for NSCLC Market Status by Type

• 3.1 Targeted Drug BRAF Inhibitors for NSCLC Type Introduction
  • 3.1.1 Dabrafenib
  • 3.1.2 Trametinib
  • 3.1.3 Lifirafenib
  • 3.1.4 Other
• 3.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market by Type
• 3.3 North America: by Type
• 3.4 Europe: by Type
• 3.5 Asia Pacific: by Type
• 3.6 Central & South America: by Type
• 3.7 Middle East & Africa: by Type

4 Global and Regional Targeted Drug BRAF Inhibitors for NSCLC Market Status by Application

• 4.1 Targeted Drug BRAF Inhibitors for NSCLC Segment by Application
  • 4.1.1 Squamous Cell Carcinoma of NSCLC
  • 4.1.2 Adenocarcinoma of NSCLC
  • 4.1.3 Large Cell Carcinoma of NSCLC
• 4.2 Global Targeted Drug BRAF Inhibitors for NSCLC Market by Application
• 4.3 North America: by Application
• 4.4 Europe: by Application
• 4.5 Asia Pacific: by Application
• 4.6 Central & South America: by Application
• 4.7 Middle East & Africa: by Application

5 Global Targeted Drug BRAF Inhibitors for NSCLC Market Status by Region

• 5.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market by Region
• 5.2 North America Targeted Drug BRAF Inhibitors for NSCLC Market Status
• 5.3 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Status
• 5.4 Asia Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Status
• 5.5 Central & South America Targeted Drug BRAF Inhibitors for NSCLC Market Status
• 5.6 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Status

6 North America Targeted Drug BRAF Inhibitors for NSCLC Market Status

• 6.1 North America Targeted Drug BRAF Inhibitors for NSCLC Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Targeted Drug BRAF Inhibitors for NSCLC Market Status

• 7.1 Europe Targeted Drug BRAF Inhibitors for NSCLC Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Targeted Drug BRAF Inhibitors for NSCLC Market Status

• 8.1 Asia Pacific Targeted Drug BRAF Inhibitors for NSCLC Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Targeted Drug BRAF Inhibitors for NSCLC Market Status

• 9.1 Central & South America Targeted Drug BRAF Inhibitors for NSCLC Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market Status

• 10.1 Middle East & Africa Targeted Drug BRAF Inhibitors for NSCLC Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Type and by Application

• 12.1 Global Targeted Drug BRAF Inhibitors for NSCLC Sales Value Forecast (2022-2027)
• 12.2 Global Targeted Drug BRAF Inhibitors for NSCLC Forecast by Type
• 12.3 Global Targeted Drug BRAF Inhibitors for NSCLC Forecast by Application

13 Global Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Region/Country

• 13.1 Global Targeted Drug BRAF Inhibitors for NSCLC Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Novartis
  • 14.1.1 Company Information
  • 14.1.2 Targeted Drug BRAF Inhibitors for NSCLC Product Introduction
  • 14.1.3 Novartis Targeted Drug BRAF Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 BeiGene
  • 14.2.1 Company Information
  • 14.2.2 Targeted Drug BRAF Inhibitors for NSCLC Product Introduction
  • 14.2.3 BeiGene Targeted Drug BRAF Inhibitors for NSCLC Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis

...

15 Conclusion

16 Methodology

This report provides a comprehensive analysis of current global Targeted Drug BRAF Inhibitors for NSCLC market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Targeted Drug BRAF Inhibitors for NSCLC industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Targeted Drug BRAF Inhibitors for NSCLC market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Targeted Drug BRAF Inhibitors for NSCLC Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Targeted Drug BRAF Inhibitors for NSCLC market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Targeted Drug BRAF Inhibitors for NSCLC Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Targeted Drug BRAF Inhibitors for NSCLC industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Dabrafenib
Trametinib
Lifirafenib
Other

Segmented by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Novartis
BeiGene